Back to top
more

Veracyte (VCYT)

(Real Time Quote from BATS)

$32.03 USD

32.03
391,481

-0.25 (-0.77%)

Updated Sep 17, 2025 03:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Now the Right Time to Hold on to Charles River Stock?

by Zacks Equity Research

CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.

Zacks Equity Research

Best Momentum Stocks to Buy for February 13th

by Zacks Equity Research

VCYT and NTRS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 13, 2025.

Zacks Equity Research

IRadimed (IRMD) Lags Q4 Earnings Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of -2.22% and 1.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain HOLX Stock in Your Portfolio Now

by Zacks Equity Research

Hologic's strength in the molecular diagnostics wing instills optimism among investors. Yet, a dull macroeconomic environment raises concerns.

Zacks Equity Research

New Strong Buy Stocks for February 13th

by Zacks Equity Research

SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.

Zacks Equity Research

Should You Add Penumbra Stock to Your Portfolio Right Now?

by Zacks Equity Research

PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.

Zacks Equity Research

MYGN Stock Might Rise on Collaboration With CancerCARE

by Zacks Equity Research

Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter's network with access to the MyRisk Hereditary Cancer Test.

Zacks Equity Research

Should Investors Hold Chemed Stock in Their Portfolio Now?

by Zacks Equity Research

CHE stays on investors' radar due to its robust prospects in the VITAS business and the resilient Roto-Rooter arm.

Zacks Equity Research

STXS Stock Gains Following the First Order for its GenesisX

by Zacks Equity Research

Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months.

Zacks Equity Research

ResMed Q2 Earnings and Revenues Beat, Stock Up in Pre-Market

by Zacks Equity Research

RMD's stellar second-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.

Zacks Equity Research

Thermo Fisher Q4 Earnings and Revenues Top Estimates, Stock Up

by Zacks Equity Research

In the fourth quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.

Zacks Equity Research

Here's Why You Should Add PODD Stock to Your Portfolio Now

by Zacks Equity Research

Insulet stays on investors' radar owing to its solid progress with Omnipod 5 and strong solvency position.

Brian Bolan headshot

Brian's Big Idea: Healthcare Stocks

by Brian Bolan

Look at 3 healthcare stocks and the Healthcare Innovators service at Zacks.com.

Zacks Equity Research

CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0

by Zacks Equity Research

ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States.

Zacks Equity Research

Reasons to Retain ABT Stock in Your Portfolio Now

by Zacks Equity Research

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Zacks Equity Research

Expanding EPD Business Supports ABT Stock Amid Macro Issues

by Zacks Equity Research

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Zacks Equity Research

Is Thermo Fisher Stock Worth Holding on to in Your Portfolio?

by Zacks Equity Research

TMO continues to capture investors' attention due to its innovative product launches and trusted partnership status.

Zacks Equity Research

MYGN Stock Gains Following the Launch of Know More Sooner

by Zacks Equity Research

Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive and prenatal genetic testing.

Zacks Equity Research

Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market

by Zacks Equity Research

ABT delivers a strong underlying base business performance for the fourth quarter of 2024.

Zacks Equity Research

Prestige Consumer Stock Up 29.9% in a Year: What's Behind the Surge?

by Zacks Equity Research

PBH sees remarkable gains from long-term brand-building strategies and developing the e-commerce channel.

Zacks Equity Research

Emerging Market Expansion Supports ZBH Stock Amid Macro Issues

by Zacks Equity Research

Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.

Zacks Equity Research

Globus Medical Surges 62.1% in a Year: What's Driving the Stock?

by Zacks Equity Research

GMED's strong synergies from the NuVasive merger and robust performance in the musculoskeletal solutions space bode well for investors.

Zacks Equity Research

Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock

by Zacks Equity Research

Valneva reports positive data from its Phase 3 - VLA1553-321 study of the IXCHIQ vaccine.

Zacks Equity Research

Reasons to Retain TNDM Stock in Your Portfolio for Now

by Zacks Equity Research

A robust diabetes market and several strategic developments raise investors' optimism for Tandem Diabetes.

Zacks Equity Research

BSX Stock Rises on Positive Data Announcement at the AF Symposium

by Zacks Equity Research

Boston Scientific announces favorable study data for its FARAPULSE PFA system and WATCHMAN FLX device at the AF Symposium 2025.